About « bioZhena’s Weblog

About

bioZhena Corporation is a medical consumer electronic technology developer, with a significant intellectual property. An associated technology is provided for optional use by medical professionals. We plan on having a marketable product ready within 7 months of funding, and profitability within 2 – 3 years. We are located in the Fort Collins, Colorado area of the U.S.

Here is the bioZhena founder’s profile:

http://www.linkedin.com/ppl/webprofile?action=vmi&trk=ppro_viewmore&id=3526343

or (in case LinkedIn won’t do)

http://profiles.yahoo.com/vaclavkirsner

In one brief sentence: We have invented the new technology of ovulography™, fundamental to women’s health and lifestyle. We have a personal fertility status monitor for home use by women, and a data management system for physicians who can receive the folliculogenesis data from their patients.

Our personal self-diagnostic device, the Ovulona™, tells the woman in plain English (or another language) whether today is one of the three days that she can become pregnant.

How? We monitor the process that causes menstrual cycles and is fundamental to women’s health. Primary use is for reproductive management: birth control and aiding the achievement of pregnancy. But there is much more, including an automatic screening for cervical cancer, management of PMS/PMDD and management of hormone therapy, to name just a few uses that come with the core technology.

To wit: Ours is a unique and disruptive technology.

Only this Ovulona device can provide to the woman at home the interpreted fertile status results in plain language for an immediate use, and provide data of unequaled accuracy. This is why ours is the only diagnostic tool that can be used for birth control.

Only our technology can perform an automatic cervical cancer screen in the background, free of anxiety, discomfort and high cost (as associated with the Pap smear). We also plan to incorporate a therapeutic function into the Ovulona device. All this will add to the consumer appeal of our core product line, already well documented.